Owlstone Medical Ltd, a Cambridge, England, UK-based diagnostics company developing a breathalyzer for disease, received an investment from Aviva Ventures, the venture capital arm of global insurance company Aviva plc.
The investment takes Owlstone Medical’s total funding to $23.5m (£19.3m) since its spin-out from Owlstone in 2016. In conjunction with it, Dr Doug Wright, Medical Director at Aviva, joined as an Observer to the Owlstone Medical Board.
The company will use the funds to drive test adoption and commercialization of its Breath Biopsy® platform.
Led by Billy Boyle, co-founder and CEO, Owlstone Medical is leveraging proprietary and proven Field Asymmetric Ion Mobility Spectrometry (FAIMS) technology in its disease breathalyzer product range. FAIMS measures volatile organic compound (VOC) metabolites in patient’s breath or biospecimens which are specific to disease. Measurement of VOC biomarkers allows non-invasive diagnosis of disease at a very early stage.